Cell Therapeutics Inc. or "CTI" (CTIC) announced that the United States Food and Drug Administration or the "FDA" informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee or "ODAC" meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application or "NDA".
The FDA indicated that it plans to reschedule the meeting as soon as the FDA can determine a schedule that would allow them to reconvene the advisory panel. Also, the company said this meeting is an open public forum for the presentation and discussion of safety and efficacy information contained in the pixantrone NDA for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma or NHL.
For comments and feedback: editorial@rttnews.com